AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33530298
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement (protein-rich beverage powder fortified with calcium 600 mg, vitamin D 400 IU, and vitamin K 55 mcg per daily serving)
Trial: 33530298
Drug: Placebo supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplement (low-protein non-fortified isocaloric beverage powder)
Trial: 35270660
Drug: 12-week motor
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week motor intervention, 60 min per session, twice per week
Trial: 34282598
Drug: Lisinopril and
RxNorm normalized name: lisinopril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril and Verapamil
Trial: 34282598
Drug: Lisinopril alone
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril alone
Trial: 35486073
Drug: Fecal microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota transplantation (FMT) with 30-g and 60-g donor feces
Trial: 35670873
Drug: Gefapixant 300
RxNorm normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Gefapixant 300 mg BID for 1 week, followed by gefapixant 600 mg BID for 2 weeks
Trial: 34371102
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for substance use (up to 12 sessions over 14 weeks)
Trial: 34371102
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy targeting depression (CBT-D)
Trial: 34371102
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for substance use
Trial: 35854374
Drug: Red LED
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red LED therapy
Trial: 35854374
Drug: Infrared LED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrared LED therapy
Trial: 33795167
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of 88% sucrose (SUC)
Trial: 33795167
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of placebo (PLA)
Trial: 34238628
Drug: Integrated cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated cognitive behavioral therapy (I-CBT)
Trial: 33173385
Drug: Concurrent CRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent CRT (CCRT)
Trial: 33053113
Drug: Escitalopram (5‐10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (5‐10 mg once per day, orally; n=49)
Trial: 35942814
Drug: Intermittent tiotropium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent tiotropium bromide 5 µg for 7 to 14 days during respiratory tract infections and as-needed albuterol sulfate 0.2 mg (n = 27)
Trial: 35942814
Drug: Twice-daily fluticasone
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily fluticasone propionate 125 µg for 7 to 14 days during respiratory tract infections and as-needed albuterol sulfate 0.2 mg (n = 25)
Trial: 35942814
Drug: As-needed albuterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As-needed albuterol sulfate 0.2 mg alone (n = 28)
Trial: 33951448
Drug: Selective laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective laser trabeculoplasty (SLT) as a first-line treatment
Trial: 33951448
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment as a first-line treatment
Trial: 32178692
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of omega-3 and plant sterols
Trial: 34159762
Drug: Enarodustat 20
RxNorm normalized name: Enarodustat
DrugBank: Enarodustat (DB14985)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Enarodustat 20 mg
Trial: 34159762
Drug: Enarodustat 150
RxNorm normalized name: Enarodustat
DrugBank: Enarodustat (DB14985)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Enarodustat 150 mg (supratherapeutic dose)
Trial: 34159762
Drug: Moxifloxacin (positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (positive control, 400 mg)
Trial: 33028396
Drug: Xanthohumol 24
RxNorm normalized name: Xanthohumol
DrugBank: Xanthohumol (DB15359)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanthohumol 24 mg/day for 8 weeks
Trial: 34304146
Drug: Active tDCS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tDCS (twice-daily, 20-min, 2-mA for 5 days)
Trial: 35733213
Drug: Single-dose denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single-dose denosumab 60 mg subcutaneous injection
Trial: 34228066
Drug: Cytisine (1.5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytisine (1.5-mg capsules taken 6 times daily for 25 days)
Trial: 34228066
Drug: Varenicline (0.5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (0.5-mg tablets titrated to 1 mg twice daily for 84 days)
Trial: 33674988
Drug: Melatonin 6
RxNorm normalized name: melatonin 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 6 mg/day for 12 weeks
Trial: 32333877
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg cinacalcet per day plus 60 mg denosumab subcutaneously every 6 months (combination group)
Trial: 32333877
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg denosumab subcutaneously every 6 months (denosumab group)
Trial: 34496116
Drug: Picosecond Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picosecond Nd:YAG laser treatment
Trial: 34404907
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion
Trial: 37753690
Drug: Niacinamide-containing body
RxNorm normalized name: Niacinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Niacinamide-containing body emollients plus cleansing gel (T2)
Trial: 32987917
Drug: Abscisic acid
RxNorm normalized name: Abscisic Acid
DrugBank: Abscisic Acid (DB16829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abscisic acid (ABA) treatment for 3 months
Trial: 37541745
Drug: Dexamethasone intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intravitreal implant 0.7 mg (DEX)
Trial: 32798050
Drug: Guideline Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline Daily Amounts (%GDA)
Trial: 32243009
Drug: VasH300 (300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VasH300 (300 mg CWE/day, n = 32)
Trial: 32243009
Drug: VasH600 (600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VasH600 (600 mg CWE/day, n = 32)
Trial: 36113537
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg bulevirtide with tenofovir disoproxil fumarate (TDF)
Trial: 36113537
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg bulevirtide with TDF
Trial: 36113537
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bulevirtide with TDF
Trial: 33768641
Drug: Skin protection
RxNorm normalized name: NeutrapHor 1% Skin Protection Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin protection products (various formulations)
Trial: 33009690
Drug: Monthly video
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly video consultations as an add-on to regular care
Trial: 32493441
Drug: Anakinra (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (100mg daily subcutaneous injection for up to 28 days)
Trial: 32493441
Drug: Siltuximab (11mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siltuximab (11mg/kg single intravenous injection)
Trial: 32493441
Drug: Tocilizumab (8mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8mg/kg single intravenous injection, max 800mg)
Trial: 32493441
Drug: Anakinra and
RxNorm normalized name: anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra and Siltuximab (combination treatment)
Trial: 32493441
Drug: Anakinra and
RxNorm normalized name: anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra and Tocilizumab (combination treatment)
Trial: 36018219
Drug: Test eldecalcitol
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test eldecalcitol soft capsules
Trial: 36018219
Drug: Reference eldecalcitol
RxNorm normalized name: Decalcitrol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference eldecalcitol soft capsules
Trial: 32672829
Drug: Cold Atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold Atmospheric Plasma (CAP) therapy
Trial: 36027496
Drug: KCl supplementation
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KCl supplementation (24mmol thrice daily for 5 days)
Trial: 39774588
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg per day)
Trial: 32171877
Drug: Laser therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapies (PBT and PDT)
Trial: 33092653
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules with the same appearance and characteristics, four times per day for two weeks
Trial: 33059754
Drug: Ivermectin treatment
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin treatment
Trial: 32387055
Drug: Ranibizumab (PRN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (PRN dosing schedule)
Trial: 32387055
Drug: Ranibizumab (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (monthly dosing schedule)
Trial: 36125830
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose immunosuppression
Trial: 32795544
Drug: Dronabinol therapy
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol therapy
Trial: 34750933
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (NB-UVB, fractional CO2 laser, topical bimatoprost 0.01%)
Trial: 34750933
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (NB-UVB, fractional CO2 laser)
Trial: 39252484
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor (SSRI)
Trial: 32178568
Drug: Sevoflurane-based combined
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane-based combined intravenous and inhalation anesthesia (group S)
Trial: 32178568
Drug: Propofol-based total
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-based total intravenous anesthesia (group P)
Trial: 32146521
Drug: Uterosacral ligament
RxNorm normalized name: human ligament preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uterosacral ligament suspension (ULS)
Trial: 33588930
Drug: Visual method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual method of oral hygiene education
Trial: 33588930
Drug: Auditory method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auditory method of oral hygiene education
Trial: 33588930
Drug: Kinesthetic method
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesthetic method of oral hygiene education
Trial: 35939599
Drug: Ibrutinib (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (420 mg/day for 3 cycles)
Trial: 36670365
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO)
Trial: 34617505
Drug: Cognitive-behavioral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral and well-being therapy (CBT/WBT)
Trial: 34973240
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (tamsulosin (0.2 mg/day) plus mirabegron (50 mg/day))
Trial: 34085479
Drug: Deep-tissue thread
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep-tissue thread embedding therapy
Trial: 34085479
Drug: Shallow-tissue thread
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shallow-tissue thread embedding therapy
Trial: 33038432
Drug: Emricasan 25
RxNorm normalized name: Emricasán
DrugBank: Emricasan (DB05408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emricasan 25 mg
Trial: 35109898
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care alone (which may include mask noninvasive ventilation, high-flow nasal oxygen, or standard oxygen therapy)
Trial: 33302654
Drug: Internet plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet plus graded diagnosis and treatment strategy
Trial: 34032151
Drug: Yukgunja-Tang (YGJT)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yukgunja-Tang (YGJT) administered at 3.0 g twice a day for 4 weeks (total of 56 times)
Trial: 35617974
Drug: Ointment
RxNorm normalized name: Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment
Trial: 34069981
Drug: 4.0 g·d−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 g·d−1 β-alanine (BA) for four weeks
Trial: 39432252
Drug: Intravenous cangrelor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cangrelor
Trial: 35342997
Drug: Vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 20 mg once daily (QD) for 6 weeks
Trial: 35342997
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once daily (QD) for 6 weeks
Trial: 35342997
Drug: Vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 20 mg twice daily (BID) for 2 weeks followed by QD for 4 weeks
Trial: 35342997
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg BID for 2 weeks followed by QD for 4 weeks
Trial: 35186107
Drug: Lianhua Qingke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lianhua Qingke (LH) tablets (4 tablets, three times a day for 14 days)
Trial: 35186107
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine treatment without LH tablets)
Trial: 32526195
Drug: Oseltamivir (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (75 mg twice daily for 5 days)
Trial: 33556032
Drug: EPICOS (tenofovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPICOS (tenofovir disoproxil/emtricitabine vs hydroxychloroquine vs combination therapy vs placebo)
Trial: 32503727
Drug: Regadenoson (A2AR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regadenoson (A2AR agonist), continuous infusion starting at the time of skin incision, maximum dose of 1.44 µg/kg/min for 12 hours
Trial: 35917364
Drug: Single-dose albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose albendazole
Trial: 33837574
Drug: Soticlestat oral
RxNorm normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat oral solution, single ascending doses up to 1350 mg
Trial: 33837574
Drug: Soticlestat tablets
RxNorm normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat tablets under fed conditions
Trial: 33837574
Drug: Soticlestat tablets
RxNorm normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat tablets under fasting conditions
Trial: 34655698
Drug: Other antidepressants
RxNorm normalized name: Other antidepressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antidepressants (fluoxetine, paroxetine, escitalopram, citalopram, duloxetine, moclobemide, mirtazapine, bupropion)
Trial: 36914957
Drug: Aspirin group
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin group
Trial: 32045010
Drug: OSA patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSA patients without treatment
Trial: 32045010
Drug: OSA patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSA patients with treatment (continuous positive airway pressure or surgery)
Trial: 33051276
Drug: Emergency treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency treatment with Levetiracetam or Phenytoin
Trial: 35487792
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D Supplementation (4,000 IU daily for 30 days)
Trial: 34098739
Drug: Twirla (2.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twirla (2.3 mg ethinyl estradiol and 2.6 mg levonorgestrel)
Trial: 36352762
Drug: Tregopil 30
RxNorm normalized name: Insulin tregopil
DrugBank: Insulin tregopil (DB11568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tregopil 30 mg
Trial: 36352762
Drug: Tregopil 45
RxNorm normalized name: Insulin tregopil
DrugBank: Insulin tregopil (DB11568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tregopil 45 mg
Trial: 33158423
Drug: Oral neuromuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral neuromuscular training with an oral device (Muppy®) for 5 weeks
Trial: 33579525
Drug: Insulin stimulation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin stimulation in cultures of normal human granulosa cells in vitro
Trial: 33579525
Drug: Insulin concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin concentration of 100 nmol/L for 12 hours
Trial: 36201360
Drug: Ozoralizumab 30
RxNorm normalized name: benralizumab 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozoralizumab 30 mg
Trial: 36201360
Drug: Ozoralizumab 80
RxNorm normalized name: Ozoralizumab
DrugBank: Ozoralizumab (DB12014)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozoralizumab 80 mg
Trial: 32759439
Drug: Pectoral nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectoral nerve block with ropivacaine 0.375% 30 ml
Trial: 32759439
Drug: Thoracic paravertebral
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic paravertebral block with ropivacaine 0.5% 20 ml
Trial: 33308429
Drug: Monovalent OPV2
RxNorm normalized name: rotavirus, monovalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent OPV2 (1 or 2 doses)
Trial: 33308429
Drug: Novel OPV2‐c1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel OPV2‐c1 (1 or 2 doses)
Trial: 33308429
Drug: Novel OPV2‐c2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel OPV2‐c2 (1 or 2 doses)
Trial: 33308429
Drug: Novel OPV2‐c1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel OPV2‐c1 (2 doses) in IPV-vaccinated participants
Trial: 33308429
Drug: Novel OPV2‐c2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel OPV2‐c2 (2 doses) in IPV-vaccinated participants
Trial: 33308429
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 doses) in IPV-vaccinated participants
Trial: 33308429
Drug: Novel OPV2
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel OPV2 candidates (1 dose)
Trial: 33308429
Drug: Monovalent OPV2
RxNorm normalized name: rotavirus, monovalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent OPV2 (1 dose)
Trial: 32857106
Drug: Cochlear implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implant
Trial: 37143040
Drug: Liraglutide (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.2 mg/day)
Trial: 33037801
Drug: Etodolac (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac (300 mg)
Trial: 35441926
Drug: Active group
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active group with support tool app for medication intake reminders and motivational messages